[Skip to Content]
[Skip to Content Landing]
Views 321
Citations 0
Correction
May 2019

Error in Table 2

JAMA Intern Med. 2019;179(5):733. doi:10.1001/jamainternmed.2019.1493

In the article titled “Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program”1 published in the October 2018 print issue of JAMA Internal Medicine, there was an error in the second-to-last column heading of Table 2. The heading “Risks-Outweigh-Benefits Vote, No., Yes/No/Abstention” should have been “Benefits-Outweigh-Risks Vote, No., Yes/No/Abstention.” This article has been corrected online.

References
1.
Jones  LC, Dhruva  SS, Redberg  RF.  Assessment of clinical trial evidence for high-risk cardiovascular devices approved under the Food and Drug Administration Priority Review Program.  JAMA Intern Med. 2018;178(10):1418-1420. doi:10.1001/jamainternmed.2018.3649PubMedGoogle ScholarCrossref
×